STOCKS TELEGRAPH

Author: Maria Masood

  • Positive Clinical Results: Tiziana Life Sciences PLC (TLSA) Stock Rising in Early Trading.

    Positive Clinical Results: Tiziana Life Sciences PLC (TLSA) Stock Rising in Early Trading.

    Tiziana Life Sciences PLC (TLSA) is a late-stage biotherapeutics enterprise focused on the development of groundbreaking therapeutics. The company’s nasal, and oral therapies have an edge over intravenous delivery. Two lead product candidates of the company include intranasal foralumab and milciclib.

    The price of TLSA stock during the early trading of March 10, 2022, was last checked to be $0.96 with a vertical gain of 25.27%.

    TLSA: Events and Happenings

    On March 10, 2022, TLSA reported optimistic clinical results in the treatment of Secondary Progressive Multiple Sclerosis, following the conclusion of six months of dosage with foralumab. Biological and clinical developments were observed in the patient along with good tolerability using the company’s innovative immunotherapeutics.

    On March 01, 2022, TLSA updated on its publication of data of the highly prognostic potential of StemPrintER for risk of distant reappearance in breast cancer patients in the European Journal of Cancer. On February 10, 2022, TLSA announced its Executive management’s participation at the Virtual BIO CEO & Investor Conference 2022 held on February 14-15, 2022.

    On February 04, 2022, TLSA informed the press about the modified submission of IND application of foralumab to the FDA for its assessment in patients with Crohn’s Disease.

    TLSA: Key Financials

    On September 24, 2021, TLSA reported its interim financial statement for the first half of 2021 ended June 30, 2021. Some of the key aspects are as follows.

    EPS

    Basic and diluted loss attributed to the equity owners per share in H1 2021 was reported to be £12.5 million or 7.4 pence comparable to £3.91 million or 2.6 pence in the same half of 2020. The company noted a considerable gain in its loss over the year.

    Conclusion

    TLSA stock dropped by 82% from the past year as the pandemic laid the financial conditions down globally. Recently, in the early trading, the company’s stock showed signs of improvement as it proclaimed positive clinical outcomes for foralumab.

  • AST SpaceMobile, Inc. (ASTS) Stock Diving in Premarket, Here’s What you Should Know.

    AST SpaceMobile, Inc. (ASTS) Stock Diving in Premarket, Here’s What you Should Know.

    AST SpaceMobile, Inc. (ASTS) is a pioneer company making the preliminary and internationally acclaimed cellular broadband network in space to function with the standard mobile device based on its IP and patent platform. The company’s expertise is on a mission to remove the connectivity breaks faced by mobile users.

    The price of ASTS stock during the regular trading of March 9, 2022, was $9.78 with a sharp increase of 44.8%. At the last check of the premarket on March 10, 2022, the stock dipped by 9.41%.

    ASTS: Events and Happenings

    On March 9, 2022, ASTS announced its entry into a multi-launch contract with Space Exploration Technologies Corp. The contract emphasizes the unveiling of the initial BlueBird satellite along with the summer launch of the BlueWalker 3 test satellite.

    ASTS: Key Financials

    On November 15, 2021, ASTS reported its consolidated financial report for the third fiscal quarter of 2021 ended September 30, 2021. Some of the key features are as follows.

    Revenue

    Revenue in the third quarter of 2021 was observed to be $2.45 million against $2.09 million in the same quarter in 2020. The company’s revenue gained over the year by $0.36 million. The actual revenue was in-line with the estimations.

    EPS

    Net income per diluted share attributed to the common stockholders in Q3 2021 was $4.11 million or $0.07 as compared to a net loss of $553 million in the comparable period of 2020. The company experienced a substantial reduction in its net loss over the year. Also, its actual EPS was in-line with the estimations.

    On October 12, 2022, ASTS reported that its CEO presented the company at the prestigious Rakuten Optimism 2021 on October 13, 2021.

    Conclusion

    ASTS stock inclined 18% YTD as the company’s strong strategies dug it out of the economic constraints of the pandemic. The recent premarket stock decline is likely attributed to shedding the gain as a result of yesterday’s announcement of the multi-launch contract by the company.

  • Direct Digital Holdings, Inc. (DRCT) Stock Sinking in Premarket. Here’s What Happened.

    Direct Digital Holdings, Inc. (DRCT) Stock Sinking in Premarket. Here’s What Happened.

    Direct Digital Holdings, Inc. (DRCT) conveys advanced advertising portfolios under one parent company. The company’s Sell-side portfolio Colossus SSP delivers the extensive general market reach and diverse media assets to its advertisers. The operating companies of the group include Huddled Masses and Orange142, which offer considerable ROI for middle-market promoters. The company’s solutions achieve 56,000 customers on daily basis, generating approximately 44 billion per month impressions across display, in-app, and CTV.

    The price of DRCT stock during the regular trading of March 9, 2022, was $2.49 with a steep rise of 107.5%. At the last check of the premarket on March 10, 2022, the stock lost its momentum by 16.4%.

    DRCT: Events and Happenings

    On March 9, 2022, DRCT reported that Orange142 has been nominated for the Pigeon Forge Department of Tourism as the digital agency of record. The term of the contract is 5 years. The 7,000 resident’s town saw a financial effect of up to $2 billion in 2021from tourism.

    DRCT: CEO Comments

    Speaking at the occasion, DRCT CEO Mark Walker stated that the company works when the expertise and technology are utilized to locate a customer’s meticulous requirements and make exclusive strategies. He further added that the exquisiteness of these collaborations lies in their potential to improve the financial wellbeing of a community overall.

    On March 2, 2022, DRCT updated that it will release its financial statement for Q4 ended December 31, 2021, on March 29, 2022. The company’s management will also host a webcast and conference call. On February 10, 2022, DRCT announced the preliminary pricing of its underwritten public offering of 2,800,000 cohorts. Each cohort consisted of one common stock share and one warrant for the acquisition of one common stock share at a public purchase price of $5.50 per cohort.

    Conclusion

    DRCT stock is 17% down the period it commenced trading on NASDAQ. In Wednesday’s regular session, the company’s stock rallied by 107% following the official announcement by the company regarding the Orange142 nomination. In Thursday’s premarket session, its stock lost the momentum to shed yesterday’s gain.

  • ENGlobal Corp. (ENG) Stock Recoiled Premarket, Here’s why.

    ENGlobal Corp. (ENG) Stock Recoiled Premarket, Here’s why.

    ENGlobal Corp. (ENG) is a leader in providing whole platform solutions for renewable and conventional energy globally. The company runs via two business segments including Commercial and Government sectors. The Commercial sector offers its clients with engineering, fabrication, and integration of automatic control platforms as a comprehensive packaged solution. The Governmental sector provides its government and public segment clients with its services.

    The price of ENG stock during the regular trading of March 9, 2022, was $1.64 with a decline of 20.1%. At the last check of the premarket on March 10, 2022, the stock recovered by 11.8%.

    ENG: Events and Happenings

    On March 9, 2022, ENG updated that it will host a conference call to discuss the Q4 financials for 2021 on March 10, 2022. On March 1, 2022, ENG reported the commencement of its operational services in the Permian basin in Texas. The company’s products demand in the region has been growing tremendously over the past few years in this region.

    On February 22, 2022, ENG announced its selection to provide its EPC services to a private customer. The company made an agreement for a renewable fuel plant producing 100 million gallons of aviation fuel and renewable diesel per year from feedstocks. On January 18, 2022, ENG informed the press about the receipt of acquisition orders valued at $2.2 million for the construction of 120 parking lot security trailers. The primary purpose of the trailers is to provide e-surveillance to make it safer and utilization for other remote surveillance.

    ENG: Key Financials

    On November 04, 2021, ENG reported its financial report for the third quarter ended September 25, 2021. Some of the key highlights are as follows.

    Revenue

    Revenue in the quarter in 2021 was recorded to be $5.92 million against $15.7 million for the same quarter of 2020. The company lost the revenue over the year by $9.8 million. It missed the revenue target by $5.68 million.

    EPS

    Net earnings per basic and diluted share in Q3 2021 were $2.4 million or $0.07 compared to a net loss of $1.11 million or $0.04 in the corresponding quarter of 2020. The company experienced a substantial gain in its EPS over the year. The company posted an EPS surprise by topping the estimates by $0.02.

    Conclusion

    ENG stock outperformed year-to-date by 18% as the company urged to reach international forums and take giant contracts. Checking the company’s increased stock price in the premarket, the likely reason for the gain is that it is gearing for financial statement release on March 10.

  • Salarius Pharmaceuticals, Inc. (SLRX) Stock Rebounds Aftermarket, Here’s What’s Happening.

    Salarius Pharmaceuticals, Inc. (SLRX) Stock Rebounds Aftermarket, Here’s What’s Happening.

    Salarius Pharmaceuticals, Inc. (SLRX) is a leading late-stage biotherapeutics firm engaged in developing cancer therapeutics for oncology patients. The lead pipeline candidate of the company is Seclidemstat in Phase 1/2 clinical-stage used for treating prostate, breast, ovary cancer, and tumors.

    The price of SLRX stock during the regular trading of March 9, 2022, was $0.37 with a decline of 2.40%. At the last check of the aftermarket, the stock rebounded by 13.3%.

    SLRX: Events and Happenings

    On March 03, 2022, SLRX updated that it will release its financials for the three months ended December 31, 2021, on March 10, 2022. The company will also host a conference call and webcast to discuss its corporate matters. On February 17, 2022, SLRX reported its Executive management’s participation at the Virtual Diamond Equity Research Emerging Growth Invitational 2022 Conference on February 24.

    On February 08, 2022, SLRX announced its CEO’s virtual presence at the 2022 BIO CEO & Investor Conference held on February 14-17. On January 13, 2022, SLRX informed the press about its entry into a definitive contract with DeuteRx, LLC for the acquisition of a small molecule targeted protein degradation platform or SP-3164. On December 29, 2021, SLRX reported the achievement of a dosing milestone in seclidemstat Phase 1/2 trials. The company assessed its efficacy against Ewing sarcoma and FET-rearranged sarcomas and advanced to the second lead-in safety unit.

    SLRX: Key Financials

    On November 04, 2021, SLRX released its unaudited financial report for the third quarter of fiscal 2021 ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    No revenue was recorded by the company for Q3 2021, while a grant revenue of $1.37 million was reported during the same period of 2020.

    EPS

    Net loss per share basic and diluted in the third quarter of 2021 was $3.7 million, or $0.08 compared to $1.7 million, or $0.10 in the corresponding quarter of 2020. The company experienced a substantial incline in its earnings per share over the year.

    Conclusion

    SLRX stock price dipped 74% in the last year as the restrictions were imposed globally during the pandemic. The company’s stock rebounded in aftermarket trading as it is gearing for the fourth quarter financial statement release. The revenue guidance provided by the company for the quarter is $325 thousand against -$0.08 EPS.

  • Lightbridge Corp. (LTBR) Stock Dropping After Hours, What’s Happening.

    Lightbridge Corp. (LTBR) Stock Dropping After Hours, What’s Happening.

    Lightbridge Corp. (LTBR) is an innovative nuclear fuel tech advancement business engaged in reducing carbon footprint and the production of carbon-free energy applications vital in stopping climate change. Its exclusive next-gen technology for Small Modular Reactors is Lightbridge Fuel along with light-water reactors, which augments the safety of the reactor.

    The price of LTBR stock during the regular trading of March 9, 2022, was $12.4 with a considerable gain of 29.9%. At the last check if the aftermarket, the stock loses by 7.21%.

    LTBR: Events and Happenings

    On March 09, 2022, LTBR reported that its CEO Seth Grae’s interview on FOX News Channel’s show ‘Hannity’, was being postponed. The show is hosted by Sean Hannity. On March 04, 2022, LTBR announced the interview of its CEO was on-aired on FOX Business Network’s show ‘Cavuto: Coast to Coast’, hosted by Neil Cavuto. He discussed the current Ukrainian situation at the Zaporizhzhia Nuclear Power Plant and Chernobyl,

    On February 28, 2022, LTBR updated on releasing its financials for the FY 2021 ended December 31, 2021, on March 9, 2022. The company will host a conference call on March 10, 2022. On February 25, 2022, LTBR informed the press that its CEO was interviewed by different media outlets. His schedule included

    • Interview with Newsy on February 24, in light of Ukraine-Russia conflict.
    • Interview with NBC News NOW on February 25 to discuss company’s policies, and
    • Interview with Oliver Renick of Market on Close aired on the TD Ameritrade Network on February 25 to discuss the company’s policies.

    On January 04, 2022, LTBR reported the appointment of its Vice President Dr. Aaron Totemeier to the Small Modular Reactors Working Group of the US ITA Department with immediate effect.

    LTBR: Key Financials

    On November 08, 2021, LTBR released its financial outcomes for the third fiscal quarter of 2021 ended September 30, 2021. Some of the important updates are as follows.

    Revenue

    No revenue was recorded by the company for the third fiscal quarter of 2021 as well as the same period of 2020.

    EPS

    Net loss per share basic and diluted in Q3 2021 was $1.91 million or $0.31 versus $3.06 million or $0.80 in the comparable quarter of 2020. The company noted a significant decline in its loss YoY.

    Conclusion

    LTBR stock is 106% up the past half-year. The recent drop in the stock price after hours is likely the impact of the postponement of the company’s CEO’s interview with FOX News Channel. The company’s stock is well-positioned to attract huge investment.

  • Statera Biopharma, Inc. (STAB) Stock Roaring Premarket Following Preliminary Financials Release.

    Statera Biopharma, Inc. (STAB) Stock Roaring Premarket Following Preliminary Financials Release.

    Statera Biopharma, Inc. (STAB) is a late-clinical biotherapeutics company focused on the development of innovative immunotherapies aiming at different diseases. The company’s toll-like receptor plays an important part in the innate immune system. The company’s clinical portfolio includes STAT-201for Crohn’s disease, Entolimod for hematological issues, STAT-401 for pancreatic carcinoma, and STAT-205 for COVID-19.

    The price of STAB stock in the regular trading on March 8, 2022, with a gain of 5.55% was $0.58. Its price significantly increased further by 4.31% at the last check in the premarket session on March 9, 2022.

    STAB: Events and Happenings

    On March 08, 2022, STAB reported its revised and preliminary financials for FY ended December 31, 2021. The revenues for the period were reported to be $1.48 million and showed a gain of 100% in comparison to the same period in 2020.

    On March 07, 2022, STAB updated on the recent progression of its next-generation research work building upon the activity of STAT-200 on TLRs to enhance the drug features and clinical advantage outside opioid receptors. On March 02, 2022, STAB announced STAT-205 pilot trials protocol submission to the FDA for treating post-acute COVID-19.

    On February 25, 2022, STAB informed the press about the additions to its BoDs team as Satish Chandran joined the company’s new director in place of Steve Barbarick, who resigned from the position and will continue in an advisory role.

    STAB: Key Financial

    On November 15, 2021, STAB released its financial statement for Q3 2021 ended September 30, 2021. Some of the key aspects are below.

    Revenue

    Revenue of $0.23 million was recorded in Q3 2021 against nil revenue in the same quarter of 2020. The company noticed a 100% gain in revenue over the year.

    EPS

    A basic and diluted net loss per share of $12.7 million or $0.47 was reported in the third quarter of 2021 compared to $5.7 million, or $1.84 in the same period in 2020.

    Conclusion

    STAB stock dipped by 74% YTD primarily due to the economic downfall globally. The current premarket stock drive is the influence of its preliminary fourth-quarter financial statement as it reported a record revenue in the quarter. The company observed a phenomenal gain in its revenue over the yearly period.

  • TC Biopharm (Holding) PLC (TCBP) Stock Leaping Premarket Following Positive Data Announcement.

    TC Biopharm (Holding) PLC (TCBP) Stock Leaping Premarket Following Positive Data Announcement.

    TC Biopharm (Holding) PLC (TCBP) late-stage biotherapeutics company that is primarily focused on discovering, manufacturing, and marketing the cellular therapies related to gamma-delta T cells for the cure of carcinoma and acute myeloid leukemia. The company utilizes an allogeneic method to successfully eradicate the tumors. The company is the pioneer in conducting phase 2 pivotal clinical trials in cancer. The product line of the company in Phase 2/3 trial is OmnImmune for acute myeloid leukemia and in Phase 1 trial for ImmuniStim to treat COVID-19 patients. The company is also maintaining a vigorous pipeline for futuristic indications in tumors.

    The price of TCBP stock in the regular trading on March 8, 2022, with an incline of 2.53% was $0.96. Its price further flew by 40.91% at the last check of the premarket session on March 9, 2022.

    TCBP: Events and Happenings

    On March 8, 2022, TCBP announced the optimistic interim results for its Phase 1/2 human trials assessing the efficacy, and safety data of OmnImmune or TCB-002 used in treating AML.

    TCBP: CEO Comments

    Speaking at this momentous occasion, TCBP CEO Bryan Kobel stated that the company is pleased to receive hopeful results demonstrating OmnImmune as tolerable among the patients. He further added that the outcomes underscore TCB-002 potential to become a worthwhile AML treatment shortly.

    On March 2, 2022, TCBP reported hosting a corporate call on March 8, 2022. On February 15, 2022, TCBP updated on the closure of its prior announced preliminary public offering of 4,117,648 ADS and warrants for the acquisition of approximately 8,235,296 ADS. The company received total net proceeds worth $17.5 million from the offering. On February 11, 2022, TCBP was informed about the commencement of its ADS or ordinary shares on the Nasdaq under the ticker ‘TCBP.

    Conclusion

    The company’s stock is 54% down from the beginning of trading on NASDAQ on February 11, 2022. Its stock rocketed in the premarket session today as the company announced the positive topline results from its TCB-002 clinical trials. It is one of the biggest achievements of the company in terms of grounding its position in the biotech industry.

  • Hotel GM as Madrina of Discovery Princess: Carnival Corp. & PLC (CCL) Stock Soaring Premarket

    Hotel GM as Madrina of Discovery Princess: Carnival Corp. & PLC (CCL) Stock Soaring Premarket

    Carnival Corp. & PLC (CCL) is a leisure traveling company. The company also provides shorter destination services along with owning hotels, motor coaches, and glass-domed rail cars.

    The price of CCL stock in the regular trading on March 8, 2022, with an acceleration of 2.25% was $15.8. Its price further rocketed by 7.05% at the last check of the premarket session of March 9, 2022.

    CCL: Events and Happenings

    On March 8, 2022, CCL reported that its partner Princess Cruises celebrated its Hotel GM Terri Cybuliak who is recently honored with the title of the Discovery Princess Madrina. On March 7, 2022, CCL’s partner Princess Cruises updated on the commencement of a partnership with Porsche Club as the authorized cruise vacation collaborator for its programs.

    On March 2, 2022, CCL partner Princess Cruises provided details regarding its licensing deal with NBA and WNBA Properties. It is a great opportunity for basketball fans to display their desired NBA and WNBA teams in MedallionClass vacation. On February 18, 2022, CCL’s brand Seabourn confirmed to opt into the US CDC platform for cruise ships. The cruise line will continue its operations in inoculated COVID-19 cruises, with stringent scrutiny measures placed to board the cruise.

    On February 10, 2022, CCL’s partner Princess Cruises reported a roundtrip in the 2022 summer season for the first-ever trip to Mexico, Hawaii, and the Californian Coasts. The cruises will start journeying on June 25, 2022, and will take 4-16 days for the trip.

    CCL: Key Financial

    On January 27, 2022, CCL released its annual financial statement for the full fiscal year of 2021 concluded on November 30, 2021. Some highlights are mentioned here.

    Revenue

    Full revenues of the company in the FY 2021 were $1.9 billion against $5.59 billion in the comparable FY 2020. The company observed an incline of $3.6 billion in its total revenue YoY.

    EPS

    Net loss basic and diluted during the fiscal year 2021 was $9.5 billion or $8.46 per share corresponding to $10.2 billion or $13.2 per share in the comparable FY 2020 and observed a substantial drop in its net loss YoY.

    Conclusion

    CCL stock is 42% down in the past year as the world has put more restrictions on travel-related companies during the pandemic. The conditions are getting better day by day as the global vaccination drive is continuing. The company’s stock recently swelled in the premarket trading as its collaborator announced the receipt of honor by its hotel GM. The company is also gearing for the quarterly release date and estimates a revenue of $2.27 billion versus -$1.28 EPS.

  • Q4 Financial Statement: Aquestive Therapeutics, Inc. (AQST) Stock Plunging Deep in Aftermarket

    Q4 Financial Statement: Aquestive Therapeutics, Inc. (AQST) Stock Plunging Deep in Aftermarket

    Aquestive Therapeutics, Inc. (AQST) is an international leading company providing therapeutics to patients with unmet medical needs. The company manufactures orally-administered therapeutics for the delivery of complex molecules. The product line of the company includes Sympazan for treating seizures related to Lennox-Gastaut syndrome. Also, it is focusing on developing pipeline products linked with CNS diseases and anaphylaxis.

    The price of AQST stock in the regular trading on March 8, 2022, with a drop of 4.08% was $2.82. Its price further dived by 6.03% at the last check of the aftermarket session.

    AQST: Key Financial

    On March 8, 2022, AQST reported its unaudited and consolidated financial statement for the fourth fiscal quarter of 2021 concluded December 31, 2021. Some highlights are cited here.

    Revenue

    Net revenues of the company in the fourth fiscal quarter of 2021 were $11.1 million against $7.1 million for the same quarter of the prior year. The company observed an increase of 55% in its net revenue YoY.

    EPS

    Net loss basic and diluted during Q4 2021 was $28.9 million or $0.72 per share in comparison to $20.4 million or $0.60 per share during the same period of 2020. The company noted a substantial drop in its earnings YoY.

    AQST: Events and Happenings

    On March 03, 2022, AQST reported its entry into a deal with Haisco Pharmaceutical Group Co., Ltd. for the licensing, development, and commercialization of EXSERVAN exclusively for treating amyotrophic lateral sclerosis.

    On February 28, 2022, AQST updated on its poster presentation announcing optimistic topline results from AQST-109 Phase 1 trials at the annual meeting of the American Academy of Allergy, Asthma, and Immunology held on February 25-28. On January 07, 2022, AQST informed about its top management’s participation at the Virtual H.C. Wainwright BioConnect Conference held on January 10-13, 2022.

    Conclusion

    AQST stock is down by 33% YTD. Its aftermarket stats showed a declining trend as the company announced its fourth fiscal quarter financials. The company’s EPS declined over the year but its revenue gained a hefty 55% over the year. For the first fiscal quarter of 2022, the revenue guidance of the company is $9.36 million versus -$0.46 EPS.